Last reviewed · How we verify
DTaP Vaccine B
DTaP Vaccine B stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, and pertussis pathogens.
DTaP Vaccine B stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, and pertussis pathogens. Used for Prevention of diphtheria, tetanus, and pertussis in infants and children.
At a glance
| Generic name | DTaP Vaccine B |
|---|---|
| Sponsor | Jiangsu Province Centers for Disease Control and Prevention |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
This is an inactivated combination vaccine containing diphtheria toxoid, tetanus toxoid, and acellular pertussis antigens. Upon administration, these antigens trigger both humoral (antibody-mediated) and cell-mediated immune responses, leading to the production of protective antibodies against diphtheria and tetanus toxins and against Bordetella pertussis. This provides immunological memory for long-term protection against these three bacterial diseases.
Approved indications
- Prevention of diphtheria, tetanus, and pertussis in infants and children
Common side effects
- Injection site pain, redness, or swelling
- Fever
- Irritability or fussiness
- Drowsiness
Key clinical trials
- Post-marketing Surveillance Study for the Safety of a DTaP-IPV- HB-PRP~T Vaccine in Republic of Korea
- BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies (PHASE3)
- A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants (PHASE2)
- Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa (PHASE3)
- Phase IV Clinical Study of sIPV Administration in Adolescent and Adult Populations (PHASE4)
- Immunogenicity of 2 Versus 3 Doses of Combined Hepatitis B Vaccines in 2-18 Months Old Children (PHASE4)
- Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants (PHASE1, PHASE2)
- Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DTaP Vaccine B CI brief — competitive landscape report
- DTaP Vaccine B updates RSS · CI watch RSS
- Jiangsu Province Centers for Disease Control and Prevention portfolio CI